C5a, a 74-residue polypeptide, is involved in several stages of inflammatory processes, causing chemotaxis and degranulation of leukocytes, enhancing vascular permeability, and stimulating cytokine production (2) . The C terminus of C5a is rapidly truncated in vivo to C5a des-Arg 74 (3), a plasma-stable form that has a different spectrum of bioactivity to that of intact C5a (4) . Peptide analogs of the C-terminal domain of C5a (e.g. Phe-Lys-Pro-D-Cha-Cha-D-Arg, peptide 1) (5) are reportedly full agonists at the C5a receptor (C5aR). 1 This suggests that the C terminus is solely responsible for receptor activation, the remainder of the molecule conferring high affinity binding (6 -8) . C5aR is a member of the G protein-coupled receptor superfamily (9, 10) , two of the extracellular loops (the second and third) and the N-terminal domain being essential for C5a binding (11) . The receptor N terminus is required for high affinity binding of C5a but not for receptor activation by C5a or small peptide agonists (12) , which interact with charged residues at the extracellular faces of the transmembrane helical bundle and hydrophobic residues in the core of the receptor (13) (14) (15) . The nature of the residue at position 5 of 1 has been shown to be crucial for agonist activity (5) , with substitution by bulkier, more aromatic molecules such as Trp or 1-naphthylalanine reducing agonist activity (5) . Two derivatives of 1, the linear peptide antagonist Phe-Lys-Pro-D-cyclohexylalanineTrp-D-Arg, 2, (5) and the cyclic peptide antagonist Phe-cyclo-[L-Orn-Pro-D-cyclohexylalanine-Trp-Arg], 3, have been shown to inhibit C5a binding and function at human and rat C5aR (16 -18) .
A model for the interaction of antagonist 2 with C5aR has recently been proposed using data from a yeast-based system of genetic analysis. Antagonist 2 became a full agonist at the I116A-mutated C5aR. This was interpreted as suggesting that Ile 116 in transmembrane helix 3 could be part of an activation switch that is blocked by Trp 5 in antagonist 2 (1) . An adjacent receptor residue, Val 286 , in helix 7, was also suggested to contribute to the mechanism. The C-terminal carboxylate has been shown to be involved in the interaction between 2 and C5aR, possibly at Arg 175 in helix 4 or Arg 206 in helix 5 (6, 13) . On the other hand, cyclic compound 3, in which there is no free carboxylate, is an even more potent antagonist than 2, so its antagonist properties are likely dependent upon only its Trp 5 residue, the C terminus being blocked. The side chain of the C-terminal Arg 74 residue of C5a has been shown to interact with Asp 282 at the extracellular side of helix 7 (14) . Glu 199 , near the extracellular face of helix 5, appears to interact with the side chain of Lys 68 , a residue required for full activity in agonist peptides and C5a des-Arg 74 but not intact C5a (19, 20) . 
EXPERIMENTAL PROCEDURES

Construction of Human C5aR
Mutants-The mutant C5aRs, I116A and V286A, were constructed by overlap extension mutagenesis as described previously (15) . The C5aR mutant clones were sequenced using ABI Big Dye terminator cycle sequencing kit, and the correct constructs were purified using Nucleobond kit PC500 (Macherey-Nagel). The production of the C5aR receptor mutants R175A, R175D, E199K, R206A, double mutant E199K/R206A, and D282A have been previously described (14, 19, 22, 23) .
Transfection and Cell Culture-RBL-2H3 cells were routinely cultured in Dulbecco's modified Eagle's medium plus 10% (v/v) fetal calf serum, which was supplemented with 400 mg/liter G418 for transfected cells, at 37°C, 5% CO 2 . RBL-2H3 cells were transfected by electroporation, as previously described (23) . A monoclonal antibody (S5/1; Serotec) that recognizes the N-terminal sequence of the C5aR was used to sort the highest 50% of transfected cells on a BD Biosciences Vantage flow cytometer in two rounds of fluorescence-activated cell sorting.
Production of Peptides and Recombinant Ligands-The ligands used in this study are shown in Table I . C5a, V3, C5a [Ala 74 ], and C5a des-Arg 74 were produced in Escherichia coli and purified by the methods described in Crass et al. (23) . Agonist and antagonist peptides, synthesized as described previously (21) , were supplied by Promics Pty Ltd. (Queensland, Australia). All cyclic peptide antagonists were Nacetylated at the N terminus except 3. An N-acetylated form of 3 had identical properties to the non-acetylated form at the C5aR in RBL cells (data not shown). Polypeptide C5a receptor antagonist C5aRA (24) was a generous gift from Joerg Kohl (Medizinische Hochschule, Hannover, Germany), and antagonist V2[Glu 68 ] was made as described (25) . Measurement of Receptor Activation-Receptor activation in RBL cells was measured as the release of ␤-hexosaminidase from intracellular granules as described (26) . The percentage of ␤-hexosaminidase release was calculated as a percentage of the release stimulated by a high dose of C5a (1 M). Total ␤-hexosaminidase content was determined after cell lysis with 0.1% Nonidet P-40. Assay of the antagonist activity was performed as described above except that the antagonists were added at varying concentrations for 15 min before the addition of C5a, C5a des-Arg 74 , or V3 at a final concentration of 50 or 250 nM. IC 50 , EC 50 , and S.E. values were obtained by nonlinear regression analysis using GraphPad Prism 3.0.
Chemotaxis Assay-Chemotaxis was measured using a 48-well migration chamber (Neuroprobe), with a 5-m pore polycarbonate membrane. Cells were harvested by treatment with phosphate-buffered saline plus 5 mm EDTA, resuspended in Dulbecco's modified Eagle's medium plus 0.1% bovine serum albumin at 10 6 /ml, and placed in the top chamber. Dulbecco's modified Eagle's medium plus 0.1% bovine serum albumin containing C5a, C5a des-Arg 74 , V3, or antagonist peptides was placed in the lower chamber, and the apparatus was incubated at 37°C for 2 h. Cells were mechanically removed from the upper surface of the membrane, which was then fixed in methanol for 30 s and stained with a 0.1% solution of toluidine blue in 0.1 M sodium phosphate, pH 5.5, for 10 min. The numbers of migrated cells was measured by densitometry using an imaging system (Alpha Innotech Corp.). In some cases the relationship between the observed density of staining and cell number was confirmed by counting stained cells in three fields at a 40ϫ magnification. Migration was calculated as a percentage of migration of positive control (WT-C5aR cells to 1 nM C5a) included in every experiment after subtraction of migration in the absence of ligand. All experiments were performed in triplicate, with a minimum of three repeats.
[ (18) . IC 50 and B max values were obtained by nonlinear regression and Scatchard analyses, respectively, using GraphPad Prism 3.0.
Ligand Docking to a Homology Model of C5aR-Docking studies were carried out on antagonist peptides 2 and Ac-3 using a homology model of the C5aR, 2 based on the crystal structure of bovine rhodopsin (27) . The homology model was constructed using the Homology module within InsightII molecular modeling suite (Accelrys Inc., InsightII Modeling Environment, Release 200.1, 2004, Accelrys Inc., San Diego, CA). In this model of C5aR, Arg 175 and Glu 199 are located just above the top of helices 4, and 5, respectively, but their predicted positions have a high degree of uncertainty since the model is only based on sequence homology with the transmembrane helices of rhodopsin. In contrast, Arg 206 is at the extracellular face of helix 5, and its location can be predicted with more confidence. Docking studies were carried out using the flexible ligand docking program Gold Version 2.1. The most recent and best defined (21) NMRderived solution structures of 2 (21) and Ac-3 (17) were used as starting points for ligand docking. We have created a series of structure models for C5aR either with a Cys 188 -Cys 109 disulfide bond that closes the loops onto the transmembrane regions or without a disulfide bond and loops directed away from the transmembrane region, which is then exposed for extracellular access. Models were generated using the Homology module within InsightII 2000.1. The receptors were prepared for docking by assigning charges and potentials and adjusting the side chains of specific residues where necessary (Asp ). The ligands used were based on the NMR structures that we have previously published and refined (21) for the cyclic and acyclic antagonists (17, 21) . Docking studies were carried out using Gold Versions 2.1, and results were viewed using InsightII. All modeling and docking was performed on an SGI R12000 octane work station. 
RESULTS
Expression of Mutant Human C5aR in RBL-
Tyr-Ser-Phe-Lys-Pro-Met-Pro-Leu-D-Ala-Arg Peptide 5
Tyr-Phe-Lys-Ala-Cha-Cha-Leu-D-Phe-Arg V3 C5a des-Arg 74 (C27R, E32A, E60R, D69A, Q71L)
C5a des-Arg 74 (C27R, V56A, V57A, K68E, D69N, M70T) C5aRA
Jun-pIII/Fos-C5a des-Arg 74 (H67F, D69R, M70S, Q71L, G73R)
a XXX, Phe, His, Bta, 1-Nal, 2-Nal, or homophenylalanine (hPhe).
into RBL-2H3 cells, and stable transfectants were obtained by selection with G418. Homogenous populations of cells were collected by two rounds of fluorescence-activated cell sorting, selecting for the top 50% expressing cells using an anti-C5aR monoclonal antibody. Receptor expression levels were measured by the specific binding of [ 125 I]C5a (B max ) to detect active receptor and by immunofluorescence to detect total receptor ( Fig. 1 ). By these criteria WT and I116A-C5aR binding levels were similar, but V286A-C5aR showed reduced binding of [ 125 I]C5a despite similar levels of receptor expression as shown by immunofluorescence. Degranulation in response to a high dose of C5a (1 M) was also assessed and was found to vary widely between cell lines (Fig. 1 ). I116A-C5aR had a maximal release of only 10% of total ␤-hexosaminidase, similar to that found previously for R206A-C5aR and E199K/R206A (14) . The expression and maximal secretion by cells transfected with R175A and R175D-C5aR have been also been described previously (22) . Both of these mutant receptors are activated only weakly by C5a but can be stimulated effectively by a variant of C5a des-Arg 74 (V3) isolated by selection from a phage display library (22) . R175A secretes ϳ50% of total ␤-hexosaminidase in response to 1 M V3, whereas R175D secretes to a lower maximum level. E199K-and D282A-C5aR have been shown to be expressed at high levels and to secrete substantial amounts of ␤-hexosaminidase in response to C5a (14, 23) . The strength of the degranulatory response is reduced by some mutations of C5aR (results are presented here and elsewhere e.g. Ref. 22) , an effect that does not correlate with either C5aR expression or C5a binding and may be due to partial misfolding of mutant receptor. However, the functional response used to measure the activity of ligands depends only on the contribution of properly folded receptors, and there is clearly sufficient active receptor to stimulate measurable degranulation in all cases (14) .
The Effects of Mutation of C5aR Residues on Receptor Affinity for C5aR
Ligands-The affinities of WT and mutant C5aR for the full agonist C5a and the partial agonist C5a des-Arg 74 were measured by pretreating transfected RBL cells with these agents, then incubating with 50 pM [
125 I]C5a (Table IIA) . Only the mutation of Arg 175 caused a substantial loss of affinity for C5a, with 30-and 152-fold decreases observed for R175A and R175D, respectively. In contrast, mutation of either Ile 116 or Val 286 increased affinity for C5a des-Arg 74 , whereas other mutations had no effect or caused only a small decrease (R175D). The binding of peptide ligands was increased in most cases measured, with only R175D-C5aR showing substantially decreased affinities for the ligands relative to WT-C5aR. These data suggest that mutation of these residues, with the exception of R175D, have relatively small effects on the overall energy of interaction of these ligands for the receptor.
Peptide Ligand Binding Sites on C5aR-To determine whether linear and cyclic peptide antagonists bind to the same site on C5aR, competition binding studies using radiolabeled cyclic antagonist [ 3 H]Ac-3 were performed on human PMNs (Table IIB) (Table IIB) . These data support the idea that C5a and the peptide ligands (agonist 2 and antagonist 3) bind to the same (or a very similar) site on C5aR.
The Effects of Mutation of C5aR Residues on C5aR
Agonists-The responses of mutated receptors to C5a largely correlated with binding affinity. In contrast, the response to the partial agonist C5a, des-Arg 74 was completely inhibited in several cases (R206A-, R175A-or R175D-, E199K-C5aR), suggesting a selective loss of responsiveness in the absence of the Arg 74 side chain (Table IIC) . The agonist form of the linear peptide, 1, was a superagonist at several mutant receptors (I116A-, V286A-, D282A-, R175A-or R175D-C5aR) stimulating a greater degree of activation than 1 M C5a/V3, but it failed to activate R206A-C5aR. Two other peptide agonists of C5aR, 4 and 5, also stimulated supramaximal levels of release from the receptor mutants I116A-, V286A-, D282A-C5aR. R175A-or R175D-C5aR did not respond to these peptides, whereas R206A, not activated by 1, showed a substantial response to 4 and 5. In contrast, E199K-C5aR responded well to peptide 1 but very poorly to 4 and 5. The presence of an L-Arg at the C Table I ) performed in triplicate. The maximal degranulation levels of these cell lines (filled bars) in response to 1 mM C5a are shown as the percentage of total cellular ␤-hexosaminidase mean Ϯ S.E. released into the supernatant from at least three separate experiments performed in triplicate.
terminus of peptides 4 and 5 may have been responsible for this mixed pattern of receptor activation. However, a variant of peptide 1 with L-Arg instead of D-Arg (1-L-Arg) failed to activate either R206A or E199K-C5aR, suggesting that additional factors must be involved. The C-terminal amide analog of 1 (1-amide) is a substantially weaker agonist at WT-C5aR than 1, suggesting that a C-terminal carboxylate might be important for agonist activity. Interestingly, receptors R206A-and R175A-or R175D-C5aR showed a reverse response, indicating that 1-amide was a stronger agonist at these receptors than 1.
The linear antagonist, 2, did not stimulate secretion from cells transfected with WT or mutant C5aR at concentrations up to 100 M, with the exception of I116A-C5aR. In these cells, the response to 2 had an EC 50 of 622 nM, similar to the agonist peptide 1 (Table IIC) . Antagonist 2 was, however, only a partial agonist, stimulating a maximal release of 62% of the response to 1 M C5a. In contrast, the cyclic antagonist 3 (and Ac-3) had no stimulatory effect at concentrations up to 100 M (Table IIC) but did act as a partial agonist at R175D-C5aR, stimulating cells to the same level as C5a, with an EC 50 of 2410 nM (Table  III) . , respectively, and shown here for comparison purposes. Significantly different from WT-C5aR: *, Ͻ5%; **, Ͻ 0.5%; ***, Ͻ0.005% (two-tailed t test). All experiments are n ϭ 2 or greater.
agonist activity on any mutant C5aR at concentrations of up to 3 and 10 M, respectively (data not shown). These data were confirmed by studies using chemotaxis as an even more sensitive read-out of receptor activation (Fig. 2) . WT-C5aR cells migrated very efficiently to C5a (maximum migration at 1 nM) but were less sensitive to C5a des-Arg
74
(maximum at 100 nM). In contrast, D282A-C5aR cells migrated equally well to both stimuli (maxima at 100 nM). E199K-and R206A-C5aR cells responded more strongly to C5a (maxima at 10 nM and 1 M, respectively) than to C5a des-Arg 74 (maxima Ͼ10 M in both cases). R175A (and R175D, data not shown) displayed only very weak responses to C5a, but V3 stimulated higher levels of migration (maxima at 1 nM). As expected from the degranulation data, I116A-C5aR responded quite poorly to C5a, with Ͻ50% of the migratory response of WT-C5aR cells, although the maximum response occurred at 1 nM C5a. The linear antagonist peptide 2 stimulated migration in I116A but not WT-C5aR cells, whereas the cyclic antagonist peptide 3 had no effect on either type of receptor.
The Effects of Mutation of C5aR
Residues on Antagonist Activity-The antagonist activities were initially measured by preincubating cells with antagonist, then adding C5a (or V3 for R175D-C5aR) to a final concentration of 250 nM (Fig. 3 , Table  III) . Under these conditions, 3 acted as a complete antagonist in all cases except R175D, where only 88% of the degranulation response to V3 was inhibited, with similar IC 50 values for WT and all mutant receptors (Fig. 3 , Table III ). In contrast, 2 was a full antagonist at V286A-, E199K-, R206A-, and E199K/ R206A-C5aR and a partial antagonist for both WT and I116A-C5aR (64% inhibition at 100 M antagonist) but had no significant effect on R175D-C5aR (Ͻ50% inhibition at 100 M). In separate experiments at a lower dose of C5a (50 nM), 100 M 2 completely inhibited activation of WT-C5aR but inhibited only 40% of the response of I116A-C5aR, whereas 3 remained a full antagonist at both receptors (data not shown).
The Effects of Substitution at Residue 5 in Cyclic Antagonist 3-To determine the effects of the size and hydrophobicity of the side chain on the agonist activity of this peptide at WTC5aR and I116A-C5aR, the critical antagonism determining Trp residue at position 5 of 3 was substituted by a series of amino acids possessing hydrophobic side chain rings. The receptor affinities and antagonist potencies of this series of peptides have been tested on human PMNs (21) . Three peptides, 3-benzothiazolealanine (3-Bta), 3-Phe, and 3-1-naphthylalanine (3-1-Nal) bound C5aR with a similar affinity to 3 and were effective antagonists, although 3-Bta had a significantly higher IC 50 value than 3. When tested on transfected RBL cells, no agonist activity was detected with any of the peptides at concentrations below 100 M (data not shown), but at 100 M one peptide, 3-Bta, caused a significantly higher secretory response from I116A-C5aR relative to the response to 3 (Fig. 4) . 3-1-Nal did not stimulate significant levels of secretion from I116A-C5aR relative to 3, but when compared with the effects on WT-C5aR, 3-1-Nal had a significantly greater effect on I116A-C5aR (t test, p Ͻ 5%). Neither WT nor V286A-C5aR showed any significant secretory response to any of these peptides.
Receptor-Ligand Modeling-A previous model for C5aR binding to peptide 2 used a presumed interaction between Arg 6 carboxylate of 2 with Arg 206 of C5aR to orient the ligand with the receptor (1). Dockings were carried out on a model that allowed for little or no movement of the receptor residues so a different rotamer of a particular residue would produce different docking results. We have now repeated this work (Fig. 5A ) using a homology model of the C5aR created without the Cys 188 -Cys 109 disulfide bond so that the loops are open and not available for interaction during the ligand docking. We checked the model of Bourne and co-workers (1) using GOLD and automated dockings of 2 (the positions of the carbonyl oxygens from the NMR turn structure were used to restrain ligand docking). Using this alternative approach to the earlier model, we found that the D-Arg 6 side chain did not project deep within the helices (not shown) but, instead, consistently lay close to residues in the extracellular loop between helix 4 and helix 5 50 , concentration (nM) resulting in 50% inhibition of the maximum degranulation. Significantly different from WT-C5aR: *, Ͻ5%; **, Ͻ0.5%; ***, Ͻ0.005% (two-tailed t test). All experiments are n ϭ 2 or greater.
with one another, although it is not possible based on homology modeling alone to pinpoint which of these might be occurring (e.g. (1) . We have examined this proposal in detail using linear and cyclic peptide antagonists as probes to determine whether this is a general target for C5aR antagonists. The data presented in this paper contrast strikingly with the effects of I116A and V286A mutations in the human C5aR expressed in yeast, where both of these mutations caused complete loss of C5a receptor activity (1). The mutation of such "putative activation switch residues" had the general effect herein of increasing receptor affinity for C5aR ligands. In contrast, the EC 50 for I116A-C5aR activation by C5a was increased 3-fold relative to WT-C5aR. Therefore, although I116A-C5aR has a higher affinity for agonists, the mutation decreases the efficiency of receptor activation by C5a, C5a des-Arg 74 , and agonist peptide 1. Mutation at Ile 116 or Val 286 caused no change in affinity for either the linear antagonist 2 or cyclic antagonist 3, although both C5aR mutants had a higher affinity for the cyclic antagonist over the linear form. 3 was a full and potent antagonist of RBL cell degranulation through both receptors, with no significant difference in IC 50 values. In contrast, the pattern of antagonism by 2 was more complex. This peptide was a full antagonist for V286A-C5aR and R206A-C5aR but inhibited WT-C5aR and I116A-C5aR by only 60% in response to 250 nM C5a. 2 is actually a partial agonist at I116A-C5aR, and therefore secretion is a balance between the antagonistic effects of peptide on secretion induced by C5a and the agonistic effects of peptide alone. On WT-C5aR, 2 is not an agonist but failed to completely inhibit C5a activity, presumably due to competition with C5a for the ligand binding site. The cyclic peptide 3 remains a potent antagonist with no detectable agonist activity on either I116A-or V286A-C5aR despite also having Trp at position 5. The antagonist activity is unlikely to be related to the lack of a free carboxylate at the C terminus, since 1-amide is a potent agonist at WT-, I116A-, and V286A-C5aR, suggesting that simple deletion of the interaction with the C-terminal carboxylate is insufficient to generate an antagonist. Substitution of Trp 5 by different amino acids generally reduces receptor affinity and antagonist activity (21) but only the sulfur-containing heterocyclic amino acid Bta produces a cyclic peptide with significant agonist activity at I116A-C5aR relative to 3. This weak gain of agonist activity correlates with the loss of antagonist potential, as 3-Bta 5 is a less potent antagonist than 3 at WT-C5aR on PMNs. However, the gain in agonist potential at I116A of 3-Bta 5 is unexpected because Trp and Bta differ only at the heteroatom. Increased agonist activity is unlikely to be due simply to improved binding of this bulkier side chain to C5aR, because 3-Bta 5 binds PMN C5aR with an identical affinity to 3. In contrast 3-Phe 5 , with a less bulky aromatic side chain, binds to PMNs with a similar affinity to 3 but remains a potent antagonist. Interestingly, a linear peptide containing Phe at position 5 is an agonist even at WT-C5aR (5), which supports the suggestion that the cyclic peptide contains additional determinants of antagonist activity.
Although the precise mechanism of C5aR antagonism by peptides is still unclear, the differential responses to receptor mutations by cyclic versus linear hexapeptides and also the two polypeptide antagonists, C5aRA and V2 H]Ac-3 for the receptor, supporting the idea that they bind at the same or a similar site on the receptor. The significant difference between the peptides is, therefore, likely to be rigidity, cyclization having locked 3 into the turn structure, whereas the linear peptide is capable of significant deformation during binding. This ability to deform may allow side chains at position 5 of the linear peptide to interact correctly with the activation site after binding, whereas the rigidity of 3, although permitting high affinity interactions with other receptor binding sites, may prevent position 5 side chains from penetrating into the Ile 116 pocket even when Ile 116 is mutated. The cyclic constraint certainly reduces the flexibility of the antagonist, and this may also limit the capacity of the antagonist to alter shape in response to receptor mutations. This hypothesis would explain the lack of agonist activity of 3-Phe help stabilize this helix and, thus, is insensitive to this mutation. It is notable that C5aR doubly mutated at Glu 199 and Arg 206 responds to agonists such as C5a and C5a des-Arg 74 (14) and antagonists 2 and 3 in a similar fashion to R206A (data presented here).
Conclusions and Comments-Based on the balance of evidence for effects of mutations in the C5a receptor on the affinity and agonist/antagonist potencies of C5a and small peptide ligands, together with our receptor-ligand modeling studies, we suggest that terminal Arg residues of such ligands do not insert into the hydrophobic pocket in the interior of the helix bundle as previously proposed (1) . The receptor and ligand mutagenesis and modeling studies in this paper present some new testable hypotheses about the importance of charged residues in the receptor, particularly Arg 206 , Glu 199 , Arg 175 , and Asp 282 , and shed further light on the fitting of Arg side chains of small peptide ligands into the C5a receptor.
